IL2RA Antibody

What is IL2RA and why is it an important target for antibody development?

IL2RA, also known as CD25, is one of the subunits of the high-affinity IL-2 receptor, which is composed of three chains: IL2RA, IL2RB, and IL2RG. The IL2RA subunit is crucial for immune cell responses and is differentially expressed among various immune cell populations . Notably, IL2RA is constitutively expressed on regulatory T cells (Tregs) and only transiently expressed on activated effector T cells .

IL2RA is important for antibody development for several reasons:

• It serves as a key marker for identifying specific immune cell populations, particularly Tregs

• It plays a role in the regulation of immune tolerance by controlling Treg activity

• Its overexpression is associated with chemotherapy resistance and poor outcomes in certain cancers like acute myeloid leukemia (AML)

• IL2RA exhibits differential expression patterns, making it valuable for targeting specific cell populations

The high frequency of IL2RA on the surface of various hematological tumor cells makes it a promising therapeutic target, with potential applications extending to both cancer treatment and autoimmune disease management .

What types of IL2RA antibodies are available for research applications?

Several types of IL2RA antibodies are available for research purposes:

• Neutralizing antibodies: These block the interaction between IL-2 and IL2RA, preventing downstream signaling

• Non-blocking antibodies: These bind to IL2RA without hindering IL-2 binding or signaling, such as the D02 antibody

• Recombinant humanized antibodies: Engineered for specific research or therapeutic applications

• Polyclonal antibodies: Recognize multiple epitopes of IL2RA

• Monoclonal antibodies: Target specific epitopes with high precision

Different experimental applications may benefit from specific antibody types:

How can I validate the specificity of an IL2RA antibody for my experiments?

Proper validation is essential to ensure experimental reliability. Consider these methodological approaches:

• ELISA binding assays: Test specific binding to human recombinant IL2RA protein. For example, colorimetric ELISA binding assays can confirm affinity-purified antibodies' specificity for IL2RA .

• Western blot analysis:

  • Use positive control lysates from tissues known to express IL2RA (e.g., spleen tissue)

  • Include a negative control (tissues/cells with no IL2RA expression)

  • Expected band size for IL2RA is approximately 50 kDa

• Immunohistochemistry (IHC):

  • Validate using tissues with known IL2RA expression patterns

  • Perform heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

  • Block with 10% goat serum

  • Use appropriate positive controls (e.g., mouse spleen tissue, rat small intestine)

• Flow cytometry:

  • Compare staining in cells that express IL2RA (activated T cells) versus resting cells

  • Include appropriate isotype controls to rule out non-specific binding

  • Use secondary detection methods appropriate for your primary antibody

• Functional validation:

  • For neutralizing antibodies, confirm inhibition of IL-2-dependent cell proliferation

  • For non-blocking antibodies, verify continued IL-2 signaling (e.g., STAT5 phosphorylation)

What are the differences between blocking and non-blocking IL2RA antibodies and when should each be used?

Blocking and non-blocking IL2RA antibodies have fundamentally different mechanisms and applications:

Blocking (Neutralizing) Antibodies:

• Mechanism: Prevent IL-2 from binding to IL2RA, disrupting formation of the high-affinity IL-2 receptor complex

• Effect: Inhibit IL-2 signaling and downstream pathways (JAK/STAT)

• Applications: Studying IL-2 pathway dependence, immunosuppression models

• Limitations: Affect all IL2RA-expressing cells, including both regulatory and effector populations

Non-blocking Antibodies:

• Mechanism: Bind to IL2RA without hindering IL-2 binding or signaling

• Effect: Can deplete IL2RA-expressing cells while preserving IL-2 signaling in remaining cells

• Applications: Selectively targeting Tregs while preserving effector T cell function

• Example: The D02 antibody binds both human and cynomolgus monkey IL2RA with high affinity without hindering IL2RA-IL-2 binding or inhibiting IL-2 signaling

The research question should guide antibody selection:

• For studying total IL-2 pathway inhibition, use blocking antibodies

• For selective depletion of IL2RA-expressing cells while maintaining IL-2 signaling in remaining cells, consider non-blocking antibodies

• In cancer research, non-blocking antibodies like D02 show promise by exhibiting anti-tumor activity while preserving IL-2 signaling to effector T cells

How does the binding of IL2RA antibodies affect downstream signaling pathways?

The effects of IL2RA antibodies on downstream signaling depend on their binding mechanism:

Pathway Considerations:

• IL-2 binding to IL2R activates downstream pathways starting with phosphorylation of JAK1 and JAK3

• IL2RA endows T cells with the ability to compete temporally for limited IL-2

• The sustained phosphorylation of STAT5 is dependent on IL2RA expression

Effects of Different Antibody Types:

• Blocking antibodies:

  • Prevent JAK1/JAK3 phosphorylation

  • Inhibit STAT5 activation

  • Disrupt cell proliferation and survival signals

• Non-blocking antibodies:

  • Allow continued JAK/STAT signaling

  • Permit sustained STAT5 phosphorylation in remaining cells

  • May deplete cells through antibody-dependent cellular cytotoxicity (ADCC)

Research shows that IL-2/mAb CD25 complexes (clone 1A12) preferentially affect IL-2Rα^hi lymphocytes, while IL-2/mAb CD122 complexes (clone S4B6) act in an IL-2Rα-independent manner . This differential targeting can be leveraged to design experiments with precise modulation of IL-2 signaling.

Methodologically, researchers can assess these effects using:

• Phospho-flow cytometry to measure STAT5 phosphorylation

• Western blotting for signaling proteins

• Cell proliferation assays to determine functional outcomes

• Pulse assays to study sustained versus transient signaling

How can IL2RA antibodies be utilized to study regulatory T cell function in tumor microenvironments?

IL2RA antibodies are valuable tools for studying Treg function in tumor contexts:

Experimental Approaches:

• Treg depletion studies:

  • Anti-IL2RA antibodies can selectively deplete Tregs (which constitutively express high levels of IL2RA)

  • This allows assessment of tumor growth in the absence of Treg-mediated suppression

  • For example, D02 (a non-blocking IL2RA antibody) potently inhibited MC38 colon adenocarcinoma tumor growth at 10 mg/kg in IL2RA-humanized mice

• Treg/effector ratio analysis:

  • Infiltration of Tregs in the tumor microenvironment and a low ratio of effector T cells to Tregs is frequently associated with tumor progression and poor prognosis

  • IL2RA antibodies can be used to manipulate this ratio experimentally

  • Flow cytometry can quantify changes in Treg prevalence following treatment

• Mechanisms of action studies:

  • IL2RA promotes aggressiveness and stem cell-related properties in certain cancers like AML

  • Antibody-mediated inhibition can help elucidate how IL2RA contributes to these phenotypes

  • Studies have shown IL2RA promotes proliferation and cell-cycle activity while inhibiting apoptosis in AML cells

• Combination therapy evaluation:

  • IL2RA antibodies can be tested alongside other immunotherapies

  • Researchers should examine whether IL2RA antibodies synergize with checkpoint inhibitors or chemotherapeutics

  • For instance, IL2RA antibodies have been shown to inhibit leukemic cells and synergize with other antileukemic agents

What methods are optimal for assessing IL2RA antibody-mediated effects on T cell subpopulations?

Several complementary methodologies yield comprehensive insights into IL2RA antibody effects:

Flow Cytometry Approaches:

• Multi-parameter analysis to identify T cell subsets (Tregs, effector T cells, memory T cells)

• Essential markers include CD3, CD4, CD8, CD25 (IL2RA), and FOXP3 (for Tregs)

• Example: Human PBMCs treated with PHA (5 µg/mL for 24hr) then stained with Human CD25/IL-2 Ra antibody followed by APC-conjugated Anti-Human IgG Secondary Antibody

• Include appropriate isotype controls to establish specific binding

Functional Assays:

• Proliferation assays using CFSE dilution or cell counting

• Cytokine production (IFN-γ, IL-2, IL-10) by intracellular staining or ELISA

• Suppression assays to measure Treg function

• Cytotoxicity assays for effector function assessment

Signaling Analysis:

• Phospho-flow cytometry to measure STAT5 phosphorylation

• Assessment of sustained versus transient signaling using pulse assays

• Example: Culture of human effector T cells with IL-2 led to IL2RA-dependent sustained STAT5 phosphorylation

In Vivo Models:

• Humanized mouse models for evaluation of human-specific antibodies

• IL-2Rα humanized mice are valuable tools for in vivo efficacy evaluation of human IL-2Ra antibodies

• These models have T cells expressing human IL2RA that respond similarly to human cells

• Analyze changes in lymphocyte populations in blood, spleen, and tumor tissues

Molecular Analysis:

• RNA-seq to assess transcriptomic changes in T cell subsets following antibody treatment

• Chromatin accessibility assays to examine epigenetic effects

• Receptor occupancy assays to determine antibody binding in vivo

What considerations are important when using IL2RA antibodies in humanized mouse models?

Humanized mouse models present unique opportunities and challenges for IL2RA antibody research:

Model Selection:

• IL-2Rα humanized mice have had the genomic DNA covering exons 2-6 of mouse IL-2Ra gene (encoding the extracellular domain) replaced with the human IL-2Ra genomic DNA counterpart

• These models allow for testing of human-specific antibodies in an in vivo context

• Human IL-2Ra is mainly detectable on T cells in the spleen of humanized mice

Validation Approaches:

• Functional validation:

  • Verify that STAT-5 phosphorylation induced by mouse IL2 protein is blocked by anti-human IL-2Ra antibodies

  • This confirms that the functional pathways in IL-2Ra humanized mice work properly

• Population analysis:

  • Confirm that humanized mice are similar to wild-type mice in basal leukocyte subpopulations

  • Validate normal distributions of T/B cells, NK cells, DC, granulocytes, and monocytes/macrophages

Experimental Design Considerations:

• Dosing regimens should account for potential differences in antibody clearance between human and mouse systems

• For tumor studies, consider syngeneic models established in IL-2Ra humanized mice

• Example: D02 (a non-blocking IL2RA antibody) showed significant anti-tumor activity in MC38 colon adenocarcinoma models in IL2RA-humanized mice at 10 mg/kg

• Include appropriate controls including isotype-matched antibodies

Limitations and Challenges:

• Potential differences in Fc receptor biology between mice and humans may affect antibody-dependent cellular cytotoxicity

• Human IL2RA may interact differently with mouse downstream signaling components

• Consider lymphodepletion effects when interpreting results; in lymphodepleted conditions, both IL-2 and IL-15 therapy effectively augment the persistence of donor cells

How do IL2RA antibodies differ in their applications for cancer immunotherapy versus transplantation research?

IL2RA antibodies serve distinct purposes in cancer and transplantation contexts:

Cancer Immunotherapy Applications:

• Goal: Typically to enhance anti-tumor immunity

• Mechanism: Often depleting Tregs to unleash effector T cell responses

• Antibody preference: Non-blocking antibodies may be advantageous

• Example: D02, a non-blocking IL2RA antibody, exhibits significant anti-tumor activity while preserving IL-2 signaling to effector T cells

• Research findings: IL2RA promotes proliferation and inhibits apoptosis in AML cells; antibody-mediated inhibition of IL2RA inhibits leukemic cells while sparing normal hematopoietic cells

Transplantation Research Applications:

• Goal: Typically to prevent rejection by inducing immunosuppression

• Mechanism: Blocking IL-2 signaling to reduce T-cell proliferation and activation

• Antibody preference: Blocking (neutralizing) antibodies

• Examples: Basiliximab and daclizumab have been evaluated for prevention of liver transplant rejection

• Research findings: IL2RA-based induction therapy reduces rates of acute rejection events but does not reduce mortality rates in transplant patients

Methodological Differences:

• Cancer models: Focus on tumor growth inhibition, effector to Treg ratios, and survival endpoints

• Transplantation models: Focus on graft survival, rejection markers, and long-term tolerance

Dosing Considerations:

• Cancer applications may require repeated administration to maintain Treg depletion

• Transplantation applications may follow induction regimens followed by maintenance immunosuppression

What are the latest approaches for evaluating IL2RA antibody specificity across closely related receptor family members?

Ensuring specificity is crucial when working with IL2RA antibodies, as several related receptors share structural similarities:

Advanced Binding Characterization:

• Surface Plasmon Resonance (SPR):

  • Provides kinetic binding parameters (ka, kd, KD)

  • Can compare binding to IL2RA versus related receptors

  • Enables quantitative comparison between different antibodies

• Cross-reactivity panels:

  • Test binding against IL2RB, IL2RG, and other cytokine receptor family members

  • Include receptors that share components, such as IL4R, IL7R, and IL15R which also utilize the common gamma chain

• Epitope mapping:

  • Determine the specific binding regions of antibodies on IL2RA

  • Techniques include hydrogen-deuterium exchange mass spectrometry, X-ray crystallography

  • Example: The L72-FSY variant of IL-2 was shown by tandem MS to specifically cross-link with H120 of IL2Rα

Functional Discrimination Approaches:

• Signaling pathway selectivity:

  • Assess effects on STAT5 phosphorylation downstream of IL-2 versus related cytokines

  • Example: Culture of human effector T cells with hIL-2 but not hIL-15 led to IL-2Rα-dependent sustained STAT5 phosphorylation

• Cell type-specific expression:

  • Utilize panels of cells with different expression patterns of cytokine receptor components

  • Example: IL-2/mAb CD25 complexes (clone 1A12) preferentially expand IL-2Rα^hi lymphocytes, while IL-2/mAb CD122 complexes (clone S4B6) act in an IL-2Rα-independent manner

• Combination of genetic and antibody approaches:

  • Use IL2RA knockout/knockdown systems to confirm specificity

  • Example: Mutation of H120 of IL-2Rα to Ala prevented formation of a covalent complex with IL-2 variants, confirming specificity of interaction

These advanced approaches ensure that experimental observations can be confidently attributed to IL2RA-specific effects rather than to cross-reactivity with related receptors.